Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM Imaging System in Breast Conserving Surgery
NCT04440982Phase 2Terminated
- Sponsor
- Lumicell
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Lumicell. Primary endpoints: Development and validation of tumor detection algorithms in breast cancer patients receiving neoadjuvant therapy at 1 month, Number of patients with reported adverse events at 14 days and 2 more. Started Sep 2020; status: terminated.
Beyond the preview
Go deeper on NCT04440982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440982.